Skip to main content

Table 1 Demographic, disease and treatment characteristics of the study population

From: The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients

  All patients (n = 497) RA patients (n = 248) SpA patients (n = 249)
Age, mean (SD) (range) years 55.7 (13.0) (22–86) 60.8 (12.4) (24–86) 50.6 (11.6) (22–76)
Sex (% women) 62.8 81.0 44.6
Smoking at vaccination (%) 17.4 19.0 15.7
Disease duration mean (SD) (range) years 14.9 (11.2) (0–48) 15.9 (11.5) (0–48) 13.8 (10.8) (0–45)
DAS28 (SD) (range) 3.2 (1.2) (0–6.4) 3.6 (1.1) (0.6-5.9) 2.8 (1.2) (0–6.4)
DAS28 CRP at vaccination (0–10) 2.7 (0.97) (0.96-5.6) 2.9 (0.9) (0.96-4.9) 2.5 (0.98) (0.96-5.6)
HAQ at vaccination (0–3) (range) 0.7 (0.6) (0–3.0) 0.9 (0.7) (0–3.0) 0.5 (0.5) (0–2.13)
RF at vaccination (%) ---- 79.8 ----
Anti-CCP at vaccination (%) ---- 77.8 ----
HLA-B27 (%) ---- ---- 47.8
MTX at vaccination (%) 51.1 69.4 33.0
MTX + anti-TNF at vaccination (%) 31.8 35.1 32.9
Anti-TNF as monotherapy (%) 34.0 30.6 32.9
NSAIDs without other anti-rheumatic treatment (%) 17.1 0 34.1
Serious infection before vaccination (number of events) 18 13 5
Serious infection after vaccination (number of events) 27 23 4
  1. RA, rheumatoid arthritis; SpA, spondylarthropathy; DAS28, disease activity score using 28 joint counts; CRP, C-reactive protein; HAQ, health assessment questionnaire; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide; HLA-B27, human leukocyte antigen B27; MTX, methotrexate; anti-TNF, anti-tumor necrosis factor; NSAIDs, non-steroidal anti-inflammatory drugs.